Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation